BioNTech SE - ADR
BNTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$21.87B
Close$
Earnings Call Q4 2025
March 10, 2026 - AI Summary
Strong Financial Performance: BioNTech exceeded its 2025 revenue guidance with total revenues of EUR 2.9 billion, a slight increase from the previous year despite a decrease in COVID-19 vaccine sales. However, R&D expenses were approximately EUR 2.1 billion, slightly lower than the previous year, demonstrating effective cost management.
Healthier Cash Position: The company ended 2025 with EUR 17.2 billion in cash, cash equivalents, and securities, providing a robust financial foundation to support ongoing investments in late-stage oncology programs and potential commercialization efforts.
Transition to New Leadership: Co-founders Ugur Sahin and Ozlem Tureci will transition to a new independent company focused on next-generation mRNA innovations by the end of 2026. This shift raises questions about leadership stability as BioNTech navigates important late-stage trials and product launches, with the next CEO sought to have strong experience in late-stage development and commercial execution.
Exclusive for Stockcircle Pro members
Sign up
$47.94
47.1% downside
Current Fair Value
47.1% downsideOvervalued by 47.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $21.87 Billion |
|---|---|
| Enterprise Value | $13.19 Billion |
| Earnings per Share | $-4.51 |
| Beta | 1.25 |
| Outstanding Shares | 253,333,333 |
Return
| Return on Equity | -9.61% |
|---|---|
| Return on Assets | -8.39% |
| Return on Invested Capital | -9.18% |
Valuation & Multiples
| P/E Ratio | -11.5 |
|---|---|
| PEG | -9.93 |
| Price to Sales | 9.07 |
| Price to Book Ratio | 1.3 |
| Enterprise Value to Revenue | 4.99 |
| Enterprise Value to EBIT | -7.81 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 3, 2026
EPS Estimate
$0.76
Consensus analyst estimateRevenue Estimate
$1.17 B
Consensus analyst estimateNext Earnings Call
Expected Date
March 9, 2027
EPS Estimate
$-1.76
Consensus analyst estimateRevenue Estimate
$444.43 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 151.87% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.93%▼ 17.67% |
|---|---|
| Total Invested | $232.32M▼ 94.70% |
| Investors Holding | 40▼ 278.00% |
About BioNTech SE
7,807 employees
CEO: Ugur Sahin
BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including B...